Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor ConferenceGlobeNewsWire • 01/19/21
Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/13/21
UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)GlobeNewsWire • 12/15/20
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)GlobeNewsWire • 12/15/20
Rafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft TissueGlobeNewsWire • 12/01/20
Rafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of SoftGlobeNewsWire • 12/01/20
Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic CancerGlobeNewsWire • 11/10/20
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue SarcomaGlobeNewsWire • 10/29/20
A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals' Lead Compound CPI-613®️ (devimistat) for Patients With Pancreatic Cancer in JapanGlobeNewsWire • 10/20/20
Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®️ (devimistat) for Patients with Metastatic Pancreatic CancerGlobeNewsWire • 08/06/20
Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)GlobeNewsWire • 07/21/20
Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific ProgramGlobeNewsWire • 05/26/20
Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia ModelsGlobeNewsWire • 05/07/20
Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal CancerGlobeNewsWire • 05/05/20
MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/LeukemiaGlobeNewsWire • 04/28/20
Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)GlobeNewsWire • 04/23/20
Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic CancerGlobeNewsWire • 03/24/20
Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance OfficerGlobeNewsWire • 03/03/20
LipoMedix Announces Publication of Positive Phase 1 Data for Promitil® (PL-MLP) in Research Journal Investigational New DrugsGlobeNewsWire • 01/23/20
Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract CancerGlobeNewsWire • 01/21/20
Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic CancerGlobeNewsWire • 01/14/20
Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/13/20
